Table 2.
Haplotype distributions among the LCPD hips analyzed.
| Number of Evaluated LCPD Hips = 51 | |||||
|---|---|---|---|---|---|
| Low Risk * n = 31 |
Intermediate Risk * n = 14 |
High Risk * n = 6 |
|||
| A1A1–CC | 15 (48.4%) | A1A2–CT | 3 (21.4%) | A2A2–TT | 0 |
| A1A1–CT | 16 (51.6%) | A1A2–CC | 11 (78.6%) | A1A2–TT | 2 (33.3%) |
| A1A1–TT | 3 (50%) | ||||
| A2A2–CT | 1 (16.7%) | ||||
| A2A2–CC | 0 | ||||
* Low-risk haplotypes: a combination of normal homozygous status for the PlA2 (A1A1) polymorphism with homozygous normal (CC) and heterozygous (CT) status for the C677T mutation of the MTHFR gene. Intermediate-risk haplotypes: those heterozygous for the PlA2 (A1A2) polymorphism plus normal homozygous (CC) or heterozygous (CT) haplotypes for the C677T mutation of the MTHFR gene. High-risk haplotypes: a combination of the homozygous status for MTHFR (TT) or PlA2 (A2A2) genes.